Cited by 331Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell TransplantationMesenchymal stem cell research

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

Open access

Corre, J, Mahtouk, K, Attal, M, Gadelorge, M, Huynh, A, Fleury-Cappellesso, S, Danho, C, Laharrague, P, Klein, B, Rème, T, Bourin, P·2007·Leukemia

DOI 10.1038/sj.leu.2404621PMC PMC2346535

Open this paper in CoChat — free account

Abstract

Recent literature suggested that cells of the microenvironment of tumors could be abnormal as well. To address this hypothesis in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression profiling and phenotypic and functional studies in three groups of individuals: patients with MM, patients with monoclonal gamopathy of undefined significance (MGUS) and healthy age-matched subjects. Gene expression profile independently classified the BMMSCs of these individuals in a normal and in an MM group. MGUS BMMSCs were interspersed between these two groups. Among the 145 distinct genes differentially expressed in MM and normal BMMSCs, 46% may account for a tumor-microenvironment cross-talk. Known soluble factors implicated in MM pathophysiologic features (i.e. IL (interleukin)-6, DKK1) were revealed and new ones were found which are involved in angiogenesis, osteogenic differentiation or tumor growth. In particular, GDF15 was found to induce dose-dependent growth of MOLP-6, a stromal cell-dependent myeloma cell line. Functionally, MM BMMSCs induced an overgrowth of MOLP-6, and their capacity to differentiate into an osteoblastic lineage was impaired. Thus, MM BMMSCs are abnormal and could create a very efficient niche to support the survival and proliferation of the myeloma cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/sj.leu.2404621

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citation
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,354
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,330
A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction
Gregory, C. A., Gunn, W., Peister, A., & Prockop, D. J. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.02.002 · Cited by 1,568
The Role of the Wnt-Signaling Antagonist DKK1 in the Development of Osteolytic Lesions in Multiple Myeloma
Tian, E., Zhan, F., Walker, R. C., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,505
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984
Self-citation
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
(2004) · New England Journal of Medicine · doi:10.1056/nejm200406173502526 · Cited by 817

Show all 62 references

Sorted by citations

Items 101–200 of 331

CXCL8 derived from mesenchymal stromal cells supports survival and proliferation of acute myeloid leukemia cells through the PI3K/AKT pathway
Cheng, J., Li, Y., Liu, S., Jiang, Y., Ma, J., Li, W., Li, Q., & Pang, T. (2018) · The FASEB Journal · doi:10.1096/fj.201801931r · Cited by 47
The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma
Piddock, R. E., Bowles, K. M., & Rushworth, S. A. (2017) · Cancers · doi:10.3390/cancers9040029 · Cited by 47
Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region
Berenstein, R., Blau, O., Nogai, A., Waechter, M., Slonova, E., Schmidt-Hieber, M., Kunitz, A., Pezzutto, A., Doerken, B., & Blau, I. W. (2015) · BMC Cancer · doi:10.1186/s12885-015-1078-3 · Cited by 44
Dicer1 downregulation by multiple myeloma cells promotes the senescence and tumor-supporting capacity and decreases the differentiation potential of mesenchymal stem cells
Guo, J., Zhao, Y., Fei, C., Zhao, S., Zheng, Q., Su, J., Wu, D., Li, X., & Chang, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0545-6 · Cited by 45
The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value
Desantis, V., Savino, F. D., Scaringella, A., Potenza, M. A., Nacci, C., Frassanito, M. A., Vacca, A., & Montagnani, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092513 · Cited by 46
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: Identification of potential therapeutic targets
Giuliani, N., Mangoni, M., & Rizzoli, V. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.04.004 · Cited by 44
Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease
Bueno, C., Roldan, M., Anguita, E., Romero–Moya, D., Martín-Antonio, B., Rosu‐Myles, M., del Cañizo, C., Campos, F., Garcia, R., Gómez‐Casares, M. T., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.103580 · Cited by 43
IL21R expressing CD14 + CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclasts
Bolzoni, M., Ronchetti, D., Storti, P., Donofrío, G., Marchica, V., Costa, F., Agnelli, L., Toscani, D., Vescovini, R., Todoerti, K., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.153841 · Cited by 43
Endosteal and Perivascular Subniches in a 3D Bone Marrow Model for Multiple Myeloma
Braham, M. V. J., Ahlfeld, T., Akkineni, A. R., Minnema, M. C., Dhert, W. J. A., Öner, F. C., Robin, C., Lode, A., Gelinsky, M., & Alblas, J. (2018) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2017.0467 · Cited by 47
Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes
Fairfield, H., Costa, S., Falank, C., Farrell, M., Murphy, C. S., D’Amico, A., Driscoll, H., & Reagan, M. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.584683 · Cited by 42
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
Munemasa, S., Sakai, A., Kuroda, Y., Okikawa, Y., Katayama, Y., Asaoku, H., Kubo, T., Shimose, S., & Kimura, A. (2008) · International Journal of Oncology · doi:10.3892/ijo.33.1.129 · Cited by 42
Early Lymphoid Development and Microenvironmental Cues in B-cell Acute Lymphoblastic Leukemia
Purizaca, J., Meza, I., & Pelayo, R. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.03.005 · Cited by 42
Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics
García-Gómez, A. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i3.322 · Cited by 43
Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall
Tenreiro, M. M. B., Correia, M. L., & Brito, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9571-8 · Cited by 41
Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche
Tsukamoto, S., Løvendorf, M. B., Park, J., Salem, K. Z., Reagan, M. R., Manier, S., Zavidij, O., Rahmat, M., Huynh, D., Takagi, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0161-6 · Cited by 40
Osteoblast suppression in multiple myeloma bone disease
Adamik, J., Galson, D. L., & Roodman, G. D. (2018) · Journal of bone oncology · doi:10.1016/j.jbo.2018.09.001 · Cited by 40
Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy
Patel, C. G., Yee, A. J., Scullen, T. A., Nemani, N., Santo, L., Richardson, P. G. G., Laubach, J. P., Ghobrial, I. M., Schlossman, R. L., Munshi, N. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0434 · Cited by 39
Molecular Pathogenesis of Multiple Myeloma: Chromosomal Aberrations, Changes in Gene Expression, Cytokine Networks, and the Bone Marrow Microenvironment
Klein, B., Seckinger, A., Moehler, T. M., & Hose, D. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_3 · Cited by 38
Self-citation
Pharmaceutical inhibition of glycogen synthetase kinase-3β reduces multiple myeloma–induced bone disease in a novel murine plasmacytoma xenograft model
Gunn, W., Krause, U., Lee, N., & Gregory, C. A. (2010) · Blood · doi:10.1182/blood-2010-09-308171 · Cited by 38
Bone Marrow Stromal Cells From Myeloma Patients Support the Growth of Myeloma Stem Cells
Feng, Y., Wen, J., Mike, P., Choi, D. S., Eshoa, C., Shi, Z.-Z., Zu, Y., & Chang, C.-C. (2010) · Stem Cells and Development · doi:10.1089/scd.2010.0010 · Cited by 38
Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth
Li, X., Ling, W., Khan, S., & Yaccoby, S. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1620 · Cited by 37
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti–PD-L1 Treatment
Volpin, V., Michels, T., Sorrentino, A., Menevse, A. N., Knoll, G., Ditz, M., Milenkovic, V. M., Chen, C.-Y., Rathinasamy, A., Griewank, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0608 · Cited by 38
Biological, Functional and Genetic Characterization of Bone Marrow-Derived Mesenchymal Stromal Cells from Pediatric Patients Affected by Acute Lymphoblastic Leukemia
Conforti, A., Biagini, S., Bufalo, F. D., Sirleto, P., Angioni, A., Starc, N., Pira, G. L., Moretta, F., Proia, A., Contoli, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076989 · Cited by 37
Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression
Zhang, Y., Wang, C., & Li, J. J. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00532-4 · Cited by 36
Extramedullary Multiple Myeloma: Challenges and Opportunities
Ho, M., Paruzzo, L., Minehart, J. C., Nabar, N. R., Noll, J. H., Luo, T., Garfall, A. L., & Zanwar, S. (2025) · Current Oncology · doi:10.3390/curroncol32030182 · Cited by 39
Multipotent Mesenchymal Stromal Cells: Clinical Applications and Cancer Modeling
Rodrı́guez, R., Garcı́a-Castro, J., Trigueros, C., Arranz, M. G., & Menéndez, P. R. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-2098-9_13 · Cited by 38
DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia
Ozdogan, H., Dedeoğlu, B. G., Islakoğlu, Y. Ö., Aydos, A., Köse, S., Atalay, A., Yeğin, Z. A., Avcu, F., Uçkan, D., & İlhan, O. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.006 · Cited by 36
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
Schinke, C., Qu, P., Mehdi, S. J., Hoering, A., Epstein, J., Johnson, S., van Rhee, F., Zangari, M., Thanendrarajan, S., Barlogie, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2627 · Cited by 35
Isolation, Characterization, and Transplantation of Bone Marrow-Derived Cell Components with Hematopoietic Stem Cell Niche Properties
Ahmadbeigi, N., Soleimani, M., Vasei, M., Gheisari, Y., Mortazavi, Y., Azadmanesh, K., Omidkhoda, A., Janzamin, E., & Nardi, N. B. (2013) · Stem Cells and Development · doi:10.1089/scd.2013.0005 · Cited by 34
Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
Danylesko, I., Beider, K., Shimoni, A., & Nagler, A. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/753407 · Cited by 34
The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell
Zipori, D. (2010) · Cancer Microenvironment · doi:10.1007/s12307-009-0034-7 · Cited by 33
Secreted factors from metastatic prostate cancer cells stimulate mesenchymal stem cell transition to a pro‐tumourigenic ‘activated’ state that enhances prostate cancer cell migration
Ridge, S. M., Bhattacharyya, D. D., Dervan, E., Naicker, S. D., Burke, A. J., Murphy, M. J., O’Leary, K., Greene, J. P., Ryan, A. E., Sullivan, F. J., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31226 · Cited by 35
Natural Killer Cells in the Malignant Niche of Multiple Myeloma
Venglár, O., Bago, J., Motais, B., Hájek, R., & Jelı́nek, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.816499 · Cited by 34
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
Allegra, A., Innao, V., Allegra, A. G., Pugliese, M., Salvo, E. D., Ventura-Spagnolo, E., Musolino, C., & Gangemi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112822 · Cited by 30
Mesenchymal stromal cell senescence in haematological malignancies
Plakhova, N., Panagopoulos, V., Vandyke, K., Zannettino, A. C. W., & Mrozik, K. M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10069-9 · Cited by 33
Elevated Expression of APE1/Ref-1 and its Regulation on IL-6 and IL-8 in Bone Marrow Stromal Cells of Multiple Myeloma
Xie, J., Li, M., Xiang, D.-B., Jiang-hong, M., Qing, Y., Zeng, L., Yang, Z., Guan, W., & Wang, D. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.072 · Cited by 32
Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway
Zi, F., He, J.-S., Li, Y., Wu, C., Wu, W.-J., Yang, Y., Wang, L., He, D.-H., Yang, L., Zhao, Y., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29924 · Cited by 33
Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma
Bolomsky, A., Hose, D., Schreder, M., Seckinger, A., Lipp, S., Klein, B., Heintel, D., Ludwig, H., & Zojer, N. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0105-1 · Cited by 30
Self-citation
Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma
Liu, Z., Mi, F., Han, M., Tian, M., Deng, L., Meng, N., Luo, J., & Fu, R. (2021) · Clinical and Experimental Immunology · doi:10.1111/cei.13594 · Cited by 29
Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment
Montoya, M. M., van Slobbe, G. J. J., Chang, J., Zaal, E. A., & Berkers, C. R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155621 · Cited by 33
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing
Moschetta, M., Kawano, Y., Sacco, A., Belotti, A., Ribolla, R., Chiarini, M., Giustini, V., Bertoli, D., Sottini, A., Valotti, M., et al. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0399-3 · Cited by 29
Hierarchical organization and regulation of the hematopoietic stem cell osteoblastic niche
Wang, H., Zhang, P., Liu, L., & Zou, L. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.004 · Cited by 28
Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism
Fernando, R. C., Mazzotti, D. R., de Azevedo, H. F. Z., Sandes, A. F., Rizzatti, E. G., de Oliveira, M. B., Alves, V. L. F., Eugênio, A. I. P., de Carvalho, F., Dalboni, M. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38314-8 · Cited by 29
Aging of Bone Marrow Mesenchymal Stromal Cells: Hematopoiesis Disturbances and Potential Role in the Development of Hematologic Cancers
Massaro, F., Corrillon, F., Stamatopoulos, B., Meuleman, N., Lagneaux, L., & Bron, D. (2020) · Cancers · doi:10.3390/cancers13010068 · Cited by 28
A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression
Ciavarella, S., Caselli, A., Tamma, A. V., Savonarola, A., Loverro, G., Paganelli, R., Tucci, M., & Silvestris, F. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0254 · Cited by 28
Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword
Kamrani, S., Naseramini, R., Khani, P., Razavi, Z. S., Afkhami, H., Atashzar, M. R., Nasri, F., Alavimanesh, S., Saeidi, F., & Ronaghi, H. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03741-x · Cited by 27
“Notably, MM-MSCs have different gene profiles from their counterparts in normal MSCs [289, 290].”
CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease
Johnson, S., Stewart, P., Bam, R., Qu, P., Barlogie, B., van Rhee, F., Shaughnessy, J. D., Epstein, J., & Yaccoby, S. (2014) · Blood · doi:10.1182/blood-2014-02-555813 · Cited by 28
Epigenetic‐Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone Disease
Adamik, J., Roodman, G. D., & Galson, D. L. (2019) · JBMR Plus · doi:10.1002/jbm4.10183 · Cited by 27
Tumor Microenvironmental Competitive Endogenous RNA Network and Immune Cells Act as Robust Prognostic Predictor of Acute Myeloid Leukemia
Cheng, Y., Wang, X., Qi, P., Liu, C., Wang, S., Wan, Q., Liu, Y., Su, Y., Jin, L., Liu, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.584884 · Cited by 26
Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells
Despeaux, M., Labat, E., Gadelorge, M., Prade, N., Bertrand‐Michel, J., Demur, C., Récher, C., Bonnevialle, P., Payrastre, B., Bourin, P., et al. (2011) · Leukemia · doi:10.1038/leu.2011.145 · Cited by 26
Self-citation
Variation in innate immunity genes and risk of multiple myeloma
Purdue, M. P., Qing Lan, B., Menashe, I., Zheng, T., Zhang, Y., Yeager, M., Hosgood, H. D., Zahm, S. H., Chanock, S. J., Rothman, N., et al. (2010) · Hematological Oncology · doi:10.1002/hon.954 · Cited by 26
A worm gel-based 3D model to elucidate the paracrine interaction between multiple myeloma and mesenchymal stem cells
Spelat, R., Ferro, F., Contessotto, P., Warren, N. J., Marsico, G., Armes, S. P., & Pandit, A. S. (2020) · Materials Today Bio · doi:10.1016/j.mtbio.2019.100040 · Cited by 29
Detection of Morphologic Changes in Peripheral Mononuclear Cells in Hepatitis B Virus Infection Using the Beckman Coulter LH 750
Zhu, Y., Cao, X., & Xu, D. (2009) · Laboratory Hematology · doi:10.1532/lh96.09013 · Cited by 25
Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment
Bret, C., Hose, D., Reme, T. X., Kassambara, A., Seckinger, A., Meißner, T., Schved, J., Kanouni, T., Goldschmidt, H., & Klein, B. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.02.002 · Cited by 25
Self-citation
Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma
Urbaniak-Kujda, D. M., Kapelko-Slowik, K. L., Prajs, I., Dybko, J., Wołowiec, D., Biernat, M., Słowik, M., & Kuliczkowski, K. (2015) · Hematology · doi:10.1179/1607845415y.0000000043 · Cited by 24
The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis
Uchiyama, T., Kawabata, H., Miura, Y., Yoshioka, S., Iwasa, M., Yao, H., Sakamoto, S., Fujimoto, M., Haga, H., Kadowaki, N., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.502 · Cited by 25
Multiple myeloma and bone marrow mesenchymal stem cells’ crosstalk: Effect on translation initiation
Attar‐Schneider, O., Zismanov, V., Dabbah, M., Tartakover‐Matalon, S., Drucker, L., & Lishner, M. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22378 · Cited by 24
Mesenchymal stem cells gene signature in high‐risk myeloma bone marrow linked to suppression of distinct IGFBP2‐expressing small adipocytes
Mehdi, S. J., Johnson, S., Epstein, J., Zangari, M., Qu, P., Hoering, A., van Rhee, F., Schinke, C., Thanendrarajan, S., Barlogie, B., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15669 · Cited by 24
Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment
Alameda, D., Sáez, B., Lara‐Astiaso, D., Sarvide, S., Lasa, M., Alignani, D., Rodríguez, I., Gárate, S., Vilas‐Zornoza, A., Paiva, B., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.235135 · Cited by 24
La biologie des cellules souchesmésenchymateuses d’origine humaine
Charbord, P., & Casteilla, L. (2011) · médecine/sciences · doi:10.1051/medsci/2011273261 · Cited by 24
CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis
Leguit, R. J., Raymakers, R. A. P., Hebeda, K. M., & Goldschmeding, R. (2021) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-020-00602-2 · Cited by 23
CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway
Wu, D., Guo, X., Su, J., Chen, R., Berenzon, D. P., Guthold, M., Bonin, K., Zhao, W., & Zhou, X. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.11.019 · Cited by 23
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells –Implications for myeloma bone disease
Dotterweich, J., Schlegelmilch, K., Keller, A., Geyer, B., Schneider, D., Zeck, S., Tower, R. J., Ebert, R., Jakob, F. J., & Schütze, N. (2016) · Bone · doi:10.1016/j.bone.2016.08.006 · Cited by 24
Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling
Yang, H., Zheng, Y., Zhang, Y., Cao, Z., & Jiang, Y. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.07.002 · Cited by 23
Properties and potential of bone marrow mesenchymal stromal cells from children with hematologic diseases
Dimitriou, H., Linardakis, E., Martimianaki, G., Stiakaki, E., Perdikogianni, C., Charbord, P., & Kalmanti, M. (2008) · Cytotherapy · doi:10.1080/14653240701851332 · Cited by 23
A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.
Zdzisińska, B., Roliński, J., Piersiak, T., & Kandefer‐Szerszeń, M. (2009) · Folia Histochemica et Cytobiologica · doi:10.2478/v10042-009-0015-1 · Cited by 23
Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance
Fu, J. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64722 · Cited by 23
Loss of bisecting GlcNAcylation on MCAM of bone marrow stoma determined pro-tumoral niche in MDS/AML
Feng, J., Wang, Y., Li, B., Yu, X., Lei, L., Wu, J., Zhang, X., Chen, Q., Zhou, Y., Gou, J., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01748-1 · Cited by 22
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Mahtouk, K., Hose, D., Vos, J. D., Moreaux, J., Jourdan, M., Rossi, J. F., Reme, T. X., Goldschmidt, H., & Klein, B. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1758 · Cited by 22
Self-citation
Cellular microenvironment: a key for tuning mesenchymal stem cell senescence
Sun, W., Lv, J., Guo, S., & Lv, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1323678 · Cited by 21
Bone Marrow Adipose Tissue: Regulation of Osteoblastic Niche, Hematopoiesis and Hematological Malignancies
Labella, R., Vujačić, M., & Trivanović, D. I. (2023) · Stem Cell Reviews and Reports · doi:10.1007/s12015-023-10531-3 · Cited by 21
Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
Kassambara, A., Hose, D., Moreaux, J., Reme, T. X., Torrent, J., Rossi, J. F., Goldschmidt, H., & Klein, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042161 · Cited by 21
Self-citation
The role of bone morphogenetic proteins in myeloma cell survival
Holien, T., & Sundan, A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.04.009 · Cited by 21
Lenalidomide restores the osteogenic differentiation of bone marrow mesenchymal stem cells from multiple myeloma patients via deactivating Notch signaling pathway
Guo, J., Fei, C., Zhao, Y., Zhao, S., Zheng, Q., Su, J., Wu, D., Li, X., & Chang, C. (2017) · Oncotarget · doi:10.18632/oncotarget.19265 · Cited by 21
DKK1 and sclerostin are early markers of relapse in multiple myeloma
Mabille, C., Ruyssen‐Witrand, A., Degboé, Y., Gennero, I., Avet‐Loiseau, H., Roussel, M., Hébraud, B., Nigon, D., Attal, M., & Laroche, M. (2017) · Bone · doi:10.1016/j.bone.2017.10.004 · Cited by 21
Self-citation
Multi-niche human bone marrow on-a-chip for studying the interactions of adoptive CAR-T cell therapies with multiple myeloma
Ghoshal, D., Petersen, I., Ringquist, R., Kramer, L., Bhatia, E., Hu, T., Richard, A., Park, R., Corbin, J., Agarwal, S., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.123016 · Cited by 20
Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth
Teoh, H. K., Chong, P. P., Abdullah, M., Sekawi, Z., Tan, G. C., Leong, C. F., & Cheong, S. K. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.10.004 · Cited by 21
Bone marrow stromal cells in the pathogenesis of acute myeloid leukemia
Blau, O. (2014) · Frontiers in bioscience · doi:10.2741/4203 · Cited by 19
Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease
Kristensen, I. B., Christensen, J. H., Lyng, M., Møller, M. B., Pedersen, L., Rasmussen, L. M., Ditzel, H. J., & Abildgaard, N. (2013) · British Journal of Haematology · doi:10.1111/bjh.12270 · Cited by 20
Fully automated classification of bone marrow infiltration in low-dose CT of patients with multiple myeloma based on probabilistic density model and supervised learning
Martínez‐Martínez, F., Kybic, J., Lambert, L., & Mecková, Z. (2016) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2016.02.001 · Cited by 19
Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation
Dabbah, M., Attar‐Schneider, O., Zismanov, V., Matalon, S. T., Lishner, M., & Drucker, L. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1115-510rr · Cited by 19
Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma
Schneiderová, P., Pika, T., Gajdoš, P., Fillerová, R., Krömer, P., Kudělka, M., Minařík, J., Papajík, T., Ščudla, V., & Kriegová, E. (2016) · Oncotarget · doi:10.18632/oncotarget.11242 · Cited by 20
Pathogenesis and treatment of multiple myeloma bone disease
Hiasa, M., Harada, T., Tanaka, E. I., & Abe, M. (2021) · Japanese Dental Science Review · doi:10.1016/j.jdsr.2021.08.006 · Cited by 18
The bone marrow stromal compartment in multiple myeloma patients retains capability for osteogenic differentiation in vitro: defining the stromal defect in myeloma
Kassen, D., Moore, S. E., Percy, L. A., Herledan, G., Bounds, D., Rodriguez‐Justo, M., Croucher, P. I., & Yong, K. (2014) · British Journal of Haematology · doi:10.1111/bjh.13020 · Cited by 18
Serum Growth Differentiation Factor 15 Levels in Newly Diagnosed Multiple Myeloma Patients
Tarkun, P., Ateşoğlu, E. B., Mehtap, Ö., Musul, M. M., & Hacıhanefioğlu, A. (2013) · Acta Haematologica · doi:10.1159/000354835 · Cited by 18
Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling
Wang, L., Yi, W., Ma, L., Lecea, E., Hazlehurst, L. A., Adjeroh, D. A., & Hu, G. (2023) · Cancers · doi:10.3390/cancers15215148 · Cited by 17
In Vitro 3D Models of Haematological Malignancies: Current Trends and the Road Ahead?
Mattioda, C., Voena, C., Ciardelli, G., & Mattu, C. (2025) · Cells · doi:10.3390/cells14010038 · Cited by 18
The transcriptomic profile of CD138 + cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged
Storti, P., Agnelli, L., Palma, B. D., Todoerti, K., Marchica, V., Accardi, F., Sammarelli, G., Deluca, F., Toscani, D., Costa, F., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.209999 · Cited by 17
Systemic Dysfunction of Osteoblast Differentiation in Adipose-Derived Stem Cells from Patients with Multiple Myeloma
Béréziat, V., Mazurier, C., Auclair, M., Ferrand, N., Jolly, S., Marie, T., Kobari, L., Toillon, I., Delhommeau, F., Fève, B., et al. (2019) · Cells · doi:10.3390/cells8050441 · Cited by 17
Ventricular Zone Expressed PH Domain Containing 1 (VEPH1): an adaptor protein capable of modulating multiple signaling transduction pathways during normal and pathological development
Brown, T., Kollara, A., Shathasivam, P., & Ringuette, M. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0433-4 · Cited by 20
Uptake and delivery of antigens by mesenchymal stromal cells
Sánchez‐Abarca, L. I., Álvarez‐Laderas, I., Díez‐Campelo, M., Caballero‐Velázquez, T., Herrero, C., Muntión, S., Calderón, C., García‐Guerrero, E., Sanchez-Guijo, F. M., del Cañizo, C., et al. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.01.216 · Cited by 17
Mesenchymal stem/stromal cells- a principal element for tumour microenvironment heterogeneity
Sun, L., & Yao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274379 · Cited by 16
Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
Heinemann, L., Möllers, K. M., Ahmed, H. M. M., Wei, L., Sun, K., Nimmagadda, S. C., Frank, D., Baumann, A., Poos, A. M., Dugas, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.874325 · Cited by 15
Pathways to therapy resistance: The sheltering effect of the bone marrow microenvironment to multiple myeloma cells
Bhowmick, K., Suskil, M. V., Al‐Odat, O. S., Elbezanti, W. O., Jonnalagadda, S. C., Budak-Alpdoǧan, T., & Pandey, M. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33091 · Cited by 15
Targeting the Bone Marrow Microenvironment
Moschetta, M., Kawano, Y., & Podar, K. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_6 · Cited by 16
Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth
Pfeifer, S., Schreder, M., Bolomsky, A., Graffi, S., Fuchs, D., Sahota, S. S., Ludwig, H., & Zojer, N. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1259-2 · Cited by 14
Mesenchymal niches of bone marrow in cancer
Abarrategi, A., Mariñas‐Pardo, L., Mirones, I., Rincón, E., & Garcı́a-Castro, J. (2011) · Clinical & Translational Oncology · doi:10.1007/s12094-011-0706-x · Cited by 14
Ex Vivo Graft Purging and Expansion of Autologous Blood Progenitor Cell Products from Patients with Multiple Myeloma
Yang, H. Y., Robinson, S. N., Nieto, Y. L., Jones, R. J., Gocke, C. D., Lu, J., Giralt, S., Jones, R. B., Decker, W. K., Xing, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0842 · Cited by 14
Anti-leukemic therapies induce cytogenetic changes of human bone marrow-derived mesenchymal stem cells
Yeh, S., Lo, W.-J., Lin, C.-L., Liao, Y.-M., Lin, C.-Y., Bai, L., Liang, J., & Chiu, C. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1254-8 · Cited by 14
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Caraux, A., Vincent, L., Bouhya, S., Quittet, P., Moreaux, J., Requirand, G., Veyrune, J., Olivier, G., Cartron, G., Rossi, J., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.650 · Cited by 14
Self-citation

Authors: Corre, J., Mahtouk, K., Attal, M., Gadelorge, M., Huynh, A., Fleury-Cappellesso, S., Danho, C., Laharrague, P., Klein, B., Rème, T., & Bourin, P.
Affiliations: Établissement Français du Sang (FR)
Inserm (FR)
Hôpital Purpan (FR)
Centre National de la Recherche Scientifique (FR)
Corresponding author: Bourin, P
ORCID: Corre, J
Attal, M
Gadelorge, M
Huynh, A
Laharrague, P
Bourin, P
Venue: Leukemia
Publisher: Springer Science and Business Media LLC
Published: 2007-03-08
Volume: 21
Issue: 5
Pages: 1079-1088
ISSN: 0887-6924 (ISSN-L)
1476-5551
DOI: 10.1038/sj.leu.2404621
PMC: PMC2346535
OpenAlex: W2048064990
Cited by: 328
References: 62
Citations by year: 2026: 8 · 2025: 8 · 2024: 13 · 2023: 11 · 2022: 12 · 2021: 20 · 2020: 18 · 2019: 10 · 2018: 18 · 2017: 21 · 2016: 21 · 2015: 18 · 2014: 23 · 2013: 25 · 2012: 25
FWCI: 13.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Leukemia (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
HAL (submittedVersion, other-oa)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords: multiple myeloma, bone marrow mesenchymal stem cells, tumor microenvironment, monoclonal gammopathy of undetermined significance, gene expression profiling, interleukin-6, DKK1, GDF15, angiogenesis, osteogenic differentiation
MeSH terms: Adult, Aged, Bone Marrow Cells, Cell Differentiation, Female, Hematopoiesis, Humans, Male, Middle Aged, Multiple Myeloma, Osteoblasts, Cytokines, Gene Expression Profiling, Cell Proliferation, Growth Differentiation Factor 15, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks